Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy

Abstract Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade (ICB)-based therapies mainly relies on PD-1/PD-L1 and CTLA-4 blockade. However, th...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Rocío Granda-Díaz, Alejandra Martínez-Pérez, Candelaria Aguilar-García, Juan P. Rodrigo, Juana M. García-Pedrero, Segundo Gonzalez
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-08-01
Edice:	Molecular Cancer
Témata:	Immunotherapy BTLA HVEM Checkpoint blockade T cell NK cell
On-line přístup:	https://doi.org/10.1186/s12943-023-01845-4
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!